Abstract
8-(1-((5-Cyclopentenylpyridin-3-yl)methyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (1) and 8-(1-(3- cyclopentenylbenzyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one (2) are synthesized and obtained in the crystalline state for X-ray diffraction studies. In the asymmetric unit of compound 1, there are two independent molecules (A and B) having similar conformations. In the crystals of compounds 1 and 2, individual molecules are linked by pairs of N–H•••O hydrogen bonds forming A–A and B–B inversion dimers with R 22 (8) ring motifs. The dimers are stabilized by N–H•••O hydrogen bonds and are linked via C–H•••O short contact interactions, forming a three-dimensional and two-dimensional networks in 1 and 2 respectively. The network in 2 is further stabilized by a number of C–H•••π interactions. Compounds 1 and 2 have a dual dopamine D2 and serotonin 5-HT1A receptor profile.
References
M. Rowley, L. J. Bristow, and P. H. Hutson, J. Med. Chem., 44, No. 4, 477–501 (2001).
D. C. Goff and R. I. Shader, in: Schizophrenia, S. R. Hirsch and D. Weinberger (eds.), 2nd ed., Blackwell Publishing, Oxford (2002).
L. H. Lindstrom, Acta Psychiatr. Scand., 77, No. 5, 524–529 (1988).
A. Newman-Tancredi, D. Cussac, and R. Depoortere, Curr. Opin. Invest. Drugs, 8, No. 7, 539–554 (2007).
C. A. Jones and A. C. McCreary, Neuropharmacology, 55, 1056–1065 (2008).
A. Newman-Tancredi, A. B. Assie, N. Leduc, A. M. Ormiere, N. Danty, and C. Cosi, Int. J. Neuropsychopharmacol., 8, 341–356 (2005).
M. B. Assie, V. Ravailhe, V. Faucillon, and A. Newman-Tancredi, J. Pharmacol. Exp. Ther., 315, 265–272 (2005).
L. Slot, L. D. Vries, A. Newman-Tancredi, and D. Cussac, Eur. J. Pharmacol., 534, 63–70 (2006).
L. Slot, M. S. Kleven, and A. Newman-Tancredi, Neuropharmacology, 49, 996–1006 (2005).
M. S. Kleven, C. Barret-Grevoz, L. Slot, and A. Newman-Tancredi, Neuropharmacology, 49, 135–143 (2005).
R. A. Bantick, J. F. W. Deakin, and P. M. Grasby, J. Psychopharmacol., 15, 37–46 (2001).
N. Ullah, J. Med. Chem., 10, 484–496 (2014).
N. Ullah, J. Enzyme Inhib. Med. Chem., 29, No 2, 281–291(2014).
U. Ghani, N. Ullah, S. A. Ali, and H. A. Al-Muallem, Asian J. Chem., 26, 8358–8362 (2014).
N. Ullah and A. A. Al-Shaheri, Z. Naturforsch. B, 67, 253–262 (2012).
X-Area V1.35 and X-RED32 V1.31 Software, STOE & Cie GmbH, Darmstadt, Germany (2009).
G. M. Sheldrick, Acta Crystallogr., Sect A., 64, 112–122 (2008).
A. L. Spek, Acta Crystallogr., Sect. D, 65, 148–155 (2009).
C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler, and J. van de Streek, J. Appl. Crystallogr., 39, 453–457 (2006).
M. Altaf and H. Stoeckli-Evans, Acta Crystallogr., Sect. C, 66, o441–o445 (2009).
N. Ullah and H. Stoeckli-Evans, Acta Crystallogr., Sect. E, 70, o103/o104 (2014).
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © 2015 N. Ullah, M. Altaf, M. Mansha, A. O. Ba-Salem.
The text was submitted by the authors in English. Zhurnal Strukturnoi Khimii, Vol. 56, No. 7, pp. 1496-1499, November-December, 2015.
Rights and permissions
About this article
Cite this article
Ullah, N., Altaf, M., Mansha, M. et al. Crystal structures of dual dopamine D2 and serotonin 5-HT1A active arylpiperidinyl-2(1H)-3,4-dihydroquinolinones. J Struct Chem 56, 1441–1445 (2015). https://doi.org/10.1134/S0022476615070318
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0022476615070318